Stock ALLO ALLOGENE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
2.4 USD -8.05% Intraday chart for Allogene Therapeutics, Inc. +7.62% -25.23%
06-20 Allogene Therapeutics Inc. Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel as Part of First Line Treatment for Patients with Large B-Cell Lymphoma CI
06-10 Allogene Therapeutics, Inc. Announces Executive Changes CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allogene Therapeutics Inc. Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel as Part of First Line Treatment for Patients with Large B-Cell Lymphoma
Allogene Therapeutics, Inc. Announces Executive Changes
Allogene Therapeutics Prices $110 Million Offering
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development
Allogene Therapeutics Files $500 Million Mixed Shelf
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments
Aktien New York: Anleger nach US-Wirtschaftsdaten hin- und hergerissen
Aktien New York: Trübe Stimmung im Servicesektor wirkt positiv
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic
Aktien New York Ausblick: Schwächer erwartet nach Arbeitsmarktbericht
Allogene to cut 22% of its workforce
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-Based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of Car T Led by ALPHA3
Allogene Therapeutics, Inc. Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647
Allogene Therapeutics Shares Jump After Reporting Preclinical Data on AlloCAR T Product Candidate for Cancer
Allogene Therapeutics, Inc. Presents Preclinical Data on Next Generation Cloak and Dagger Technologies At the Society for Immunotherapy of Cancer Annual Meeting
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLO Stock
  4. News Allogene Therapeutics, Inc.
  5. Other languages